Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemo alone versus nivolumab plus chemotherapy with or without BMS-986205 in muscle-invasive bladder cancer
NL-OMON60972Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab, linrodostat, gemcitabine and cisplatin in bladder cancer and muscle-invasive bladder cancer (MIBC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Pathological complete response rate and Event-free survival. Started Nov 2019; status: completed.
02
Drugs
03
Conditions
bladder cancermuscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NL-OMON60972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60972.